Access to anti-retroviral drugs, male in Mauritania

Mauritania: Access to anti-retroviral drugs, male was 97.0% in 2024. ◆ Volatile

Latest (2024)
97.0%
Change on year
up 9.0%
World rank
2nd
of 141 countries
All-time high
97.0%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in Mauritania, 2000–2024

0204060801002000201220242000: 0 %2001: 0 %2002: 0 %2003: 0 %2004: 1 %2005: 2 %2006: 4 %2007: 7 %2008: 10 %2009: 13 %2010: 15 %2011: 21 %2012: 22 %2013: 25 %2014: 28 %2015: 33 %2016: 39 %2017: 46 %2018: 49 %2019: 56 %2020: 63 %2021: 73 %2022: 75 %2023: 89 %2024: 97 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in Mauritania stood at 97.0%. That is the highest value across all 25 years on record.

Compared with earlier readings it is up 9.0% on the previous year and up 246.4% over ten years.

Over the whole period, access to anti-retroviral drugs, male in Mauritania peaked at 97.0% in 2024 and was at its lowest, 0.0%, in 2000.

Mauritania ranks 2nd of 141 countries on this measure, in the top 10%.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in Mauritania, year by year

Annual values for Access to anti-retroviral drugs, male (%) in Mauritania, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.0%
2002 0.0%
2003 0.0%
2004 1.0%
2005 2.0% +100.0%
2006 4.0% +100.0%
2007 7.0% +75.0%
2008 10.0% +42.9%
2009 13.0% +30.0%
2010 15.0% +15.4%
2011 21.0% +40.0%
2012 22.0% +4.8%
2013 25.0% +13.6%
2014 28.0% +12.0%
2015 33.0% +17.9%
2016 39.0% +18.2%
2017 46.0% +17.9%
2018 49.0% +6.5%
2019 56.0% +14.3%
2020 63.0% +12.5%
2021 73.0% +15.9%
2022 75.0% +2.7%
2023 89.0% +18.7%
2024 97.0% +9.0%

Averages by decade

DecadeAverage LowestHighest Years
2000s 3.7% 0.0% 13.0% 10
2010s 33.4% 15.0% 56.0% 10
2020s 79.4% 63.0% 97.0% 5

Countries ranked near Mauritania

  1. 1 Comoros 98.0% compare
  2. 3 Cambodia 96.0% compare
  3. 4 Rwanda 95.0% compare
  4. 4 Sweden 95.0% compare
  5. 4 Zambia 95.0% compare

See the full ranking of 160 places →

More gender data for Mauritania

All data for Mauritania →

Frequently asked questions

What is access to anti-retroviral drugs, male in Mauritania?
Access to anti-retroviral drugs, male in Mauritania was 97.0% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in Mauritania?
The highest recorded value was 97.0% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in Mauritania?
The lowest recorded value was 0.0% in 2000.
How does Mauritania rank for access to anti-retroviral drugs, male?
Mauritania ranks 2nd out of 141 countries with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in Mauritania?
Over the last ten years it is up 246.4%. The long-run trend across the full record is volatile.
Where does this Mauritania data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in Mauritania. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/mauritania/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/mauritania/">Access to anti-retroviral drugs, male in Mauritania</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.